D89 |
 |
Other disorders involving the immune mechanism, not elsewhere classified  |
| |
Excludes1 |
hyperglobulinemia NOS (R77.1) monoclonal gammopathy (of undetermined significance) (D47.2)
|
Excludes2 |
transplant failure and rejection (T86.-)
|
|
| |
D89.0 |
 |
Polyclonal hypergammaglobulinemia |
| |
Benign hypergammaglobulinemic purpura | Polyclonal gammopathy NOS |
|
|
| |
D89.1 |
 |
Cryoglobulinemia |
| |
Cryoglobulinemic purpura | Cryoglobulinemic vasculitis | Essential cryoglobulinemia | Idiopathic cryoglobulinemia | Mixed cryoglobulinemia | Primary cryoglobulinemia | Secondary cryoglobulinemia |
|
|
| |
D89.2 |
|
Hypergammaglobulinemia, unspecified |
|
| |
D89.3 |
 |
Immune reconstitution syndrome |
| |
Immune reconstitution inflammatory syndrome [IRIS] |
UseAdditionalCode |
code for adverse effect, if applicable, to identify drug (T36-T50 with fifth or sixth character 5)
|
|
|
| |
D89.4 |
 |
Mast cell activation syndrome and related disorders |
| |
Excludes1 |
aggressive systemic mastocytosis (C96.21) congenital cutaneous mastocytosis (Q82.2) (non-congenital) cutaneous mastocytosis (D47.01) (indolent) systemic mastocytosis (D47.02) malignant mast cell neoplasm (C96.2-) malignant mastocytoma (C96.29) mast cell leukemia (C94.3-) mast cell sarcoma (C96.22) mastocytoma NOS (D47.09) other mast cell neoplasms of uncertain behavior (D47.09) systemic mastocytosis associated with a clonal hematologic non-mast cell lineage disease (SM-AHNMD) (D47.02)
|
|
| |
D89.40 |
 |
Mast cell activation, unspecified |
| |
Mast cell activation disorder, unspecified | Mast cell activation syndrome, NOS |
|
| | |
D89.41 |
|
Monoclonal mast cell activation syndrome |
| | |
D89.42 |
|
Idiopathic mast cell activation syndrome |
| | |
D89.43 |
 |
Secondary mast cell activation |
| |
Secondary mast cell activation syndrome |
CodeAlso |
underlying etiology, if known
|
|
| | |
D89.44 |
 |
Hereditary alpha tryptasemia |
| |
UseAdditionalCode |
code, if applicable, for: allergy status, other than to drugs and biological substances (Z91.0-) personal history of anaphylaxis (Z87.892)
|
|
| | |
D89.49 |
 |
Other mast cell activation disorder |
| |
Other mast cell activation syndrome |
|
| |
| |
D89.8 |
|
Other specified disorders involving the immune mechanism, not elsewhere classified |
| |
D89.81 |
 |
Graft-versus-host disease |
| |
CodeFirst |
underlying cause, such as: complications of transplanted organs and tissue (T86.-) complications of blood transfusion (T80.89)
|
UseAdditionalCode |
code to identify associated manifestations, such as: desquamative dermatitis (L30.8) diarrhea (R19.7) elevated bilirubin (R17) hair loss (L65.9)
|
|
| |
D89.810 |
 |
Acute graft-versus-host disease |
| |
|
| | |
D89.811 |
 |
Chronic graft-versus-host disease |
| |
|
| | |
D89.812 |
 |
Acute on chronic graft-versus-host disease |
| |
|
| | |
D89.813 |
 |
Graft-versus-host disease, unspecified |
| |
|
| | | |
D89.82 |
|
Autoimmune lymphoproliferative syndrome [ALPS] |
| | |
D89.83 |
 |
Cytokine release syndrome |
| |
CodeFirst |
underlying cause, such as: complications following infusion, transfusion and therapeutic injection (T80.89-) complications of transplanted organs and tissue (T86.-)
|
UseAdditionalCode |
code for adverse effect, if applicable, to identify immune checkpoint inhibitors and immunostimulant drugs (T45.AX5)
|
UseAdditionalCode |
code to identify associated manifestations
|
|
| |
D89.831 |
|
Cytokine release syndrome, grade 1 |
| | |
D89.832 |
|
Cytokine release syndrome, grade 2 |
| | |
D89.833 |
|
Cytokine release syndrome, grade 3 |
| | |
D89.834 |
|
Cytokine release syndrome, grade 4 |
| | |
D89.835 |
|
Cytokine release syndrome, grade 5 |
| | |
D89.839 |
|
Cytokine release syndrome, grade unspecified |
| | | |
D89.84 |
 |
IgG4-related disease |
| |
Immunoglobulin G4-related disease |
|
| | |
D89.89 |
 |
Other specified disorders involving the immune mechanism, not elsewhere classified |
| |
Excludes1 |
human immunodeficiency virus disease (B20)
|
|
| |
| |
D89.9 |
 |
Disorder involving the immune mechanism, unspecified |
| |
|
|